Back to results
US 9,849,180 B2Granted
Long-acting semi-solid lipid formulations
OwnerHui Rong Shen, Na Ganinventors
Life of this patent
Estimating the term…
Abstract
What is described is a semi-solid controlled release composition comprising a semi-solid lipid pharmaceutical active agent in a solution or a homogenous suspension, methods of using the composition for treating a disease, and methods of manufacturing the composition.
Claims7
A pharmaceutical composition, comprising
- i. a first glyceride mixture comprising one or more glycerides selected from the group consisting of (a) polyglyceryl-2-diisostearate;
- (b) a mixture of caprylic, capric, myristic, and stearic triglycerides;
- (c) bis-diglyceryl polyacyladipate-1;
- (d) glyceryl ricinoleate;
- (e) a mixture of triglycerides, diglycerides and monoglycerides of C10-C18 fatty acids;
- and (f) triglycerides of saturated C12-C18 fatty acids;
- and
- ii. meloxicam, or a fatty acid complex thereof, at a concentration of 5 to 60 wt % in the first glyceride mixture;
- wherein the pharmaceutical composition consists of a homogenous semi-solid suspension, wherein the semi-solid suspension consists of a soft paste with a viscosity of 50-2000 cPs at 30° C., and wherein the semi-solid suspension forms a depot that releases meloxicam for over two weeks when measured in vitro at 37° C.
6 more elements
A method of manufacturing a pharmaceutical composition, comprising
- i selecting-a first glyceride mixture comprising one or more glycerides selected from the group consisting of (a) polyglyceryl-2-diisostearate;
- (b) a mixture of caprylic, capric, myristic, and stearic triglycerides;
- (c) bis-diglyceryl polyacyladipate-1;
- (d) glyceryl ricinoleate;
- (e) a mixture of triglycerides, diglycerides and monoglycerides of C10-C18 fatty acids;
- and (f) triglycerides of saturated C12-C18 fatty acids;
- and
- ii homogeneously mixing meloxicam in the semi-solid mixture to 5 to 60 wt % of the pharmaceutical composition;
- wherein the pharmaceutical composition consists of a homogenous semi-solid suspension, wherein the semi-solid suspension consists of a soft paste with a viscosity of 50-2000 cPs at 30° C., and wherein the semi-solid suspension forms a depot that releases meloxicam for over two weeks when measured in vitro at 37° C.
6 more elements
Dependencies are inferred from the claim text.